Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroids.

Trial Profile

Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroids.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2015

At a glance

  • Drugs Anakinra (Primary)
  • Indications Bursitis; Inflammation; Plantar fasciitis; Tennis elbow
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top